All In Biotech

Drug Trial Radar · NCT07045311

JS207 Combination Therapy in Triple-negative Breast Cancer

JS207 Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)

Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Sep 17, 2025

Primary completion

Mar 22, 2028

Study completion Mar 22, 2029

Sponsor

Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, phase II clinical study to preliminarily evaluate the efficacy and safety of JS207 combined with 9MW2821 or albumin paclitaxel as first-line therapy in patients with recurrent or metastatic TNBC.

Conditions

  • Triple-negative Breast Cancer

Interventions

  • JS207 in combination with 9MW2821Drug

    JS207 will be administered intravenously at a dose of 10 mg/kg (D1, Q3W), 9MW2821 will be administered intravenously at a dose of 1.25 m.g/kg (D1 and D8, Q3W)

  • JS207 in combination with Albumin paclitaxelDrug

    JS207 will be administered intravenously at a dose of 10 mg/kg (D1, Q3W), Albumin paclitaxel will be administered intravenously at a dose of 125 mg/m2 (D1 and D8, Q3W).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: 2years

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The Fifth Medical Center of PLA General Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Guangdong women and children's hospital and health institute

    Guangzhou, Guangdong, China · Not yet recruiting

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China · Recruiting

  • Harbin Medical University Affiliated Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Harbin Medical University Affiliated Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhangzhou, Henan, China · Recruiting

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Recruiting

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • Nanchang People'S Hospital

    Nanchang, Jiangxi, China · Not yet recruiting

  • Jilin University First Hospital

    Changchun, Jilin, China · Recruiting

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, China · Recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Liaoning Cancer Hospital&Institute

    Shenyang, Liaoning, China · Recruiting

  • Ceneral Hosipital of Ningxia Medical University

    Yinchuan, Ningxia, China · Not yet recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xian, Shanxi, China · Recruiting

  • Xi'an International Medical Center Hospital

    Xian, Shanxi, China · Recruiting

  • Affiliated Tumor Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang Uygur Autonomous Region, China · Recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.